ACTRN12608000617369
Completed
Phase 2
A randomised placebo controlled double blind clinical trial on the effectiveness of a herbal formula to alleviate menopausal vasomotor symptoms.
Global Therapeutics Pty Ltd0 sites90 target enrollmentDecember 8, 2008
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Global Therapeutics Pty Ltd
- Enrollment
- 90
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Women with at least 12 months amenorrhoea aged between 45\-65 years.
- •2\. On average 6 episodes of vasomotor symptoms per day.
Exclusion Criteria
- •1\. Undiagnosed vaginal bleeding
- •2\. History of breast cancer or cancer
- •3\. Use of corticosteroids or anticoagulants
- •4\. Uncontrolled and/or diagnosed medication conditions likely to interfere with the study treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A randomised placebo controlled double blind clinical trial of vitamin D in the treatment of tuberculosisTuberculosisInfections and InfestationsISRCTN35212132Bandim Health Project (Guinea-Bissau)500
Completed
Not Applicable
A randomised placebo controlled double blind clinical trial comparing selenium and pentoxifylline in patients with mild Graves' orbitopathy - EUGOGO study BISRCTN16320108Academic Medical Centre (AMC) (The Netherlands)156
Completed
Phase 2
Clinical and physiological evaluation of a Chinese herbal medicine for constipation-predominant Irritable Bowel Syndrome (C-IBS Trial).Constipation-predominant Irritable Bowel SyndromeAlternative and Complementary Medicine - Herbal remediesACTRN12609000558224niversity of Western Sydney160
Not yet recruiting
Phase 3
A double blind randomised placebo controlled clinical trial for evaluating the efficacy of Eranda Patra Kshara and Hingu churna with lifestyle modification in the management of Non-alcoholic fatty liver diseaseCTRI/2023/04/052096All India Institute of Ayurveda
Completed
Phase 3
Rituximab in patients with primary Sjögren's syndromeISRCTN65360827niversity of Leeds (UK)110